DK3003343T3 - Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme - Google Patents
Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme Download PDFInfo
- Publication number
- DK3003343T3 DK3003343T3 DK14807179.8T DK14807179T DK3003343T3 DK 3003343 T3 DK3003343 T3 DK 3003343T3 DK 14807179 T DK14807179 T DK 14807179T DK 3003343 T3 DK3003343 T3 DK 3003343T3
- Authority
- DK
- Denmark
- Prior art keywords
- lymphangiogenese
- angiogenese
- peptid
- biomimetic
- treatment
- Prior art date
Links
- 230000003592 biomimetic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832290P | 2013-06-07 | 2013-06-07 | |
| PCT/US2014/041526 WO2014197892A1 (en) | 2013-06-07 | 2014-06-09 | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3003343T3 true DK3003343T3 (da) | 2020-02-03 |
Family
ID=52008639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14807179.8T DK3003343T3 (da) | 2013-06-07 | 2014-06-09 | Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9802984B2 (enExample) |
| EP (2) | EP3643318A1 (enExample) |
| JP (2) | JP6470740B2 (enExample) |
| CN (2) | CN105431162B (enExample) |
| AU (1) | AU2014274703B2 (enExample) |
| CA (1) | CA2914764C (enExample) |
| DK (1) | DK3003343T3 (enExample) |
| ES (1) | ES2774217T3 (enExample) |
| HU (1) | HUE047735T2 (enExample) |
| IL (1) | IL242760B (enExample) |
| WO (1) | WO2014197892A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| WO2016022947A1 (en) | 2014-08-07 | 2016-02-11 | The Johns Hopkins University | Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases |
| KR101748120B1 (ko) * | 2015-07-13 | 2017-06-16 | 서울대학교산학협력단 | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
| EP3377080B1 (en) | 2015-11-19 | 2024-02-14 | Asclepix Therapeutics, LLC | Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations |
| WO2018067646A1 (en) * | 2016-10-04 | 2018-04-12 | Asclepix Therapeutics, Llc | Compounds and methods for activating tie2 signaling |
| CA3063140A1 (en) * | 2017-05-08 | 2018-11-15 | Asclepix Therapeutics, Inc. | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| US11674959B2 (en) | 2017-08-03 | 2023-06-13 | The Johns Hopkins University | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors |
| WO2019075056A1 (en) | 2017-10-10 | 2019-04-18 | The Johns Hopkins University | BIODEGRADABLE BIOMIMETIC PARTICLES |
| US11697804B2 (en) | 2018-10-01 | 2023-07-11 | The Johns Hopkins University | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy |
| WO2020163601A2 (en) * | 2019-02-06 | 2020-08-13 | The University Of North Carolina At Chapel Hill | Compositions and methods for inhibiting post-surgical adhesions |
| CA3134816A1 (en) * | 2019-03-26 | 2020-10-01 | Asclepix Therapeutics, Inc. | Compositions and methods for treating ocular disease |
| US12605463B2 (en) | 2019-04-12 | 2026-04-21 | The Johns Hopkins University | Tolerogenic artificial antigen-presenting cells |
| CN113144213B (zh) * | 2021-03-23 | 2023-04-07 | 西安交通大学医学院第一附属医院 | 一种多级pH响应基因-药物共递送的纳米药物、制备方法及其应用 |
| WO2024044745A2 (en) * | 2022-08-26 | 2024-02-29 | Asclepix Therapeutics, Inc. | Formulations for intraocular delivery of peptides derived from type iv collagen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009512423A (ja) | 2005-09-12 | 2009-03-26 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 抗血管新生の活性を有する組成物及びその使用 |
| WO2007120368A2 (en) * | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| ITMI20060625A1 (it) * | 2006-03-31 | 2007-10-01 | Istituto Naz Per La Ricerca | Peptide antiangiogenico e suoi impieghi terapeutici |
| CA2666709A1 (en) * | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| WO2008085828A2 (en) | 2007-01-03 | 2008-07-17 | The Johns Hopkins University | Peptide modulators of angiogenesis and use thereof |
| WO2009135854A2 (en) * | 2008-05-06 | 2009-11-12 | Glaxo Group Limited | Encapsulation of biologically active agents |
| JP2011528566A (ja) * | 2008-07-21 | 2011-11-24 | コンプジェン リミティッド | アンジオポエチン由来ペプチド |
| WO2014066811A1 (en) | 2012-10-25 | 2014-05-01 | The Johns Hopkins University | Bioreducible poly (b-amino ester)s for sirna delivery |
| US9717694B2 (en) * | 2009-05-15 | 2017-08-01 | The Johns Hopkins University | Peptide/particle delivery systems |
| IN2012DN05099A (enExample) | 2009-12-16 | 2015-10-09 | Brigham & Womens Hospital | |
| US20120192339A1 (en) | 2010-07-28 | 2012-08-02 | Honeywell International Inc. | Flexible Body Armor Vest with Breast Plate |
| US20120270770A1 (en) * | 2010-08-03 | 2012-10-25 | Jesse Michael Jaynes | Anti-angiogenic peptides and their uses |
| WO2012079088A2 (en) | 2010-12-10 | 2012-06-14 | The Johns Hopkins University | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| JP5747312B2 (ja) | 2011-02-24 | 2015-07-15 | コニカミノルタ株式会社 | 活性光線硬化型インクジェットインク及び画像形成方法 |
| US20150272900A1 (en) | 2012-10-26 | 2015-10-01 | The Johns Hopkins University | Layer-By-Layer Approach to Co-Deliver DNA and siRNA via AuNPs: A Potential Platform for Modifying Release Kinetics |
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
-
2014
- 2014-06-09 JP JP2016518060A patent/JP6470740B2/ja active Active
- 2014-06-09 CN CN201480043222.XA patent/CN105431162B/zh not_active Expired - Fee Related
- 2014-06-09 AU AU2014274703A patent/AU2014274703B2/en not_active Ceased
- 2014-06-09 WO PCT/US2014/041526 patent/WO2014197892A1/en not_active Ceased
- 2014-06-09 EP EP19195992.3A patent/EP3643318A1/en active Pending
- 2014-06-09 ES ES14807179T patent/ES2774217T3/es active Active
- 2014-06-09 US US14/896,521 patent/US9802984B2/en active Active
- 2014-06-09 DK DK14807179.8T patent/DK3003343T3/da active
- 2014-06-09 EP EP14807179.8A patent/EP3003343B1/en active Active
- 2014-06-09 HU HUE14807179A patent/HUE047735T2/hu unknown
- 2014-06-09 CA CA2914764A patent/CA2914764C/en active Active
- 2014-06-09 CN CN201911163740.6A patent/CN110981941A/zh active Pending
-
2015
- 2015-11-24 IL IL242760A patent/IL242760B/en active IP Right Grant
-
2017
- 2017-09-22 US US15/712,890 patent/US10774112B2/en active Active
-
2019
- 2019-01-18 JP JP2019006590A patent/JP6931011B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-10 US US16/989,416 patent/US11981754B2/en active Active
-
2024
- 2024-04-08 US US18/629,218 patent/US20240391957A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2774217T3 (es) | 2020-07-17 |
| US10774112B2 (en) | 2020-09-15 |
| JP2016521712A (ja) | 2016-07-25 |
| IL242760B (en) | 2021-03-25 |
| CN105431162A (zh) | 2016-03-23 |
| CN105431162B (zh) | 2019-12-10 |
| WO2014197892A1 (en) | 2014-12-11 |
| JP6931011B2 (ja) | 2021-09-01 |
| EP3003343B1 (en) | 2019-10-23 |
| JP2019089790A (ja) | 2019-06-13 |
| US20200361993A1 (en) | 2020-11-19 |
| AU2014274703A1 (en) | 2015-12-10 |
| EP3003343A1 (en) | 2016-04-13 |
| HK1222542A1 (zh) | 2017-07-07 |
| US20180134753A1 (en) | 2018-05-17 |
| CA2914764A1 (en) | 2014-12-11 |
| US20160122390A1 (en) | 2016-05-05 |
| EP3643318A1 (en) | 2020-04-29 |
| AU2014274703B2 (en) | 2019-07-04 |
| CA2914764C (en) | 2021-10-26 |
| US11981754B2 (en) | 2024-05-14 |
| CN110981941A (zh) | 2020-04-10 |
| EP3003343A4 (en) | 2016-11-30 |
| US20240391957A1 (en) | 2024-11-28 |
| HUE047735T2 (hu) | 2020-05-28 |
| US9802984B2 (en) | 2017-10-31 |
| JP6470740B2 (ja) | 2019-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248730B (en) | Drug delivery system and method of use | |
| DK3234107T3 (da) | B-celler til in vivo-levering af terapeutiske midler | |
| DK3350157T3 (da) | Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler | |
| PL3191502T3 (pl) | Ukierunkowane dostarczanie substancji leczniczych zawierających aminę trzeciorzędową | |
| IL252172A0 (en) | Expandable drug delivery devices and method of use | |
| DK3328414T3 (da) | Sammensætning til anvendelse i fremme af sårheling | |
| DK3035955T3 (da) | Sammensætning og vaccine til behandling af lungekræft | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3204095T3 (da) | Inhalationsindretning til anvendelse i aerosolbehandling af luftsvejssygdomme | |
| DK3209681T3 (da) | Farmaceutiske sammensætninger omfattende peptidvarianter og fremgangsmåder til anvendelse deraf | |
| PL3362084T3 (pl) | Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania | |
| DK3692857T3 (da) | Indretning til levering af hudplejesammensætning | |
| HRP20181269T1 (hr) | Peptidi i sastavi za liječenje oštećenja zglobova | |
| DK3041926T3 (da) | Indretning til in-vitro-modellering af in-vivo-væv af organer | |
| DK3351239T3 (da) | Prostamid-indeholdende intraokulære implantater og fremgangsmåder til anvendelse deraf | |
| IL242760B (en) | A Biomimetic Peptide and Biodegradable Delivery Platform for the Treatment of Angiogenesis and Lymphangiogenesis-Dependent Diseases | |
| DK3049117T3 (da) | Ultralydsmedieret afgivelse af lægemidler | |
| EP3212170C0 (en) | IMPLANTABLE MEDICAL DEVICES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS | |
| DK3828203T3 (da) | Sammensætninger og fremgangsmåder til behandling af fedtvævsopbygning | |
| DK2890384T3 (da) | Lægemiddelleveringsystemer og fremgangsmåder til behandling af blærekræft omfattende oxaliplatin | |
| DK3113782T3 (da) | Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin | |
| PL3204030T3 (pl) | Terapia skojarzona zakażenia hbv i hdv | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| FI20146023A7 (fi) | Hammas- ja kielituki |